InsiderTrades

Form 4 for HAE HAEMONETICS CORP

Accepted 2023-05-17 00:00:00 ET · period of report 2023-05-15 · accession 0001127602-23-015925 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-05-17 2023-05-15 HAE Simon, Christopher Pres, CEO, Dir A - Grant — +18.2K 222.8K +9% —
D 2023-05-17 2023-05-16 HAE Simon, Christopher Pres, CEO, Dir F - Tax $89.21 -1,586 221.2K -0.7% -$141.5K
D 2023-05-17 2023-05-15 HAE Simon, Christopher Pres, CEO, Dir A - Grant $0.00 +41.2K 41.2K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-05-15 A A 18,225 — 222,792 D — — (F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F3) This number includes unvested RSUs previously reported.
2 Common Common Stock 2023-05-16 F D 1,586 $89.21 221,206 D — — (F4) Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. (F3) This number includes unvested RSUs previously reported.
3 Derivative Non-qualified Stock Option (Right to Buy) 2023-05-15 A A 41,177 $0.00 41,177 D $89.16 · — to 2030-05-15 41,177 Common Stock (F5) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.